A rapid and sensitive one-step reverse transcription polymerase chain reaction assay was developed to detect measles virus (MV) (14, 23) . The technique, however, requires experienced personnel to interpret the assay, which is subject to interobserver variability. Assays for the detection of MV-specific immunoglobulin M (IgM) and rising titers of MV-specific IgG provide additional alternatives for documentation of MV infection. Serologic methods, however, require that a convalescent-phase serum sample (IgG) be obtained and cannot be used in patients with defects in antigen-specific antibody production (e.g., human immunodeficiency virus-infected patients). Gene amplification followed by nucleic acid hybridization provides a sensitive and specific alternative method for the diagnosis of viral infections (7, 19 (Gemini Bioproducts, Calabasas, Calif.). Virus was allowed to adsorb to Vero cells (80% confluent in a 25-cm2 flask) for 4 h at 35°C in 5% CO2. The medium was removed and replaced with Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum-5 mM glutamine-100 U of penicillin per ml-100 ,ug of streptomycin per ml. Virus was harvested at 3 days when typical multinucleated giant cells covered approximately 80% of the monolayer. For experiments to determine the sensitivity of the reverse transcription (RT) polymerase chain reaction (PCR) assay, we used Edmonston MV of known titer (106 PFU/ml), which was kindly donated by Stephen Udem, New Jersey Medical School, Newark. [pH 7.0], 0.5% sarcosyl, 0.1 M 2-0-mercaptoethanol) and the RNA was extracted by the sequential addition of 50 pl of 2 M sodium acetate (pH 4.0), 500 ,ul of phenol, and 100 ,ul of chloroform-isoamyl alcohol (24:1). The suspension was vortexed for 10 s, cooled on ice for 15 min, and centrifuged at 10,000 x g for 20 min. The nucleic acid was precipitated from the aqueous phase with an equal volume of isopropanol at -20°C for 1 h; this was followed by centrifugation at 10,000 x g for 20 min. The pellet was redissolved in 150 ,u of the chaotropic solution and was precipitated again in isopropanol at -20°C for 1 h. After centrifugation for 10 min, the RNA pellet was washed with 70% ethanol and was 1034 on October 28, 2017 by guest
Despite the availability of an effective vaccine, sporadic and epidemic measles virus (MV) infection continues to occur in the United States. The clinical diagnosis of classical MV infection in the setting of a high prevalence of disease in the community poses no problem to the experienced clinician. With increasing frequency, however, patients are presenting with incomplete clinical syndromes and often lack the characteristic rash (10, 13) . In addition, sporadic outbreaks of MV have increased the importance of making an accurate and rapid diagnosis to allow implementation of public health measures to contain the spread of disease. In these situations, clinicians must rely on the laboratory for assistance in the diagnosis of MV infection. Serology, culture, and antigen detection are the currently available diagnostic modalities. While isolation of the virus in monkey kidney cells provides unequivocal evidence of MV infection, the procedure requires expedited handling of clinical sam- ples obtained early in the course of the disease and results are not available for 2 to 3 weeks. The indirect fluorescent antibody test (IFA) provides a more rapid alternative which allows MV antigen detection in nasal aspirates and urine (14, 23) . The technique, however, requires experienced personnel to interpret the assay, which is subject to interobserver variability. Assays for the detection of MV-specific immunoglobulin M (IgM) and rising titers of MV-specific IgG provide additional alternatives for documentation of MV infection. Serologic methods, however, require that a convalescent-phase serum sample (IgG) be obtained and cannot be used in patients with defects in antigen-specific antibody production (e.g., human immunodeficiency virus-infected patients). Gene amplification followed by nucleic acid hybridization provides a sensitive and specific alternative method for the diagnosis of viral infections (7, 19) . We used oligonucleotide primers and a probe which recognize highly conserved regions of the MV matrix gene for use in a gene amplification assay. We report here the results of this assay for the detection of the MV 500 ,ul of phenol, and 100 ,ul of chloroform-isoamyl alcohol (24:1). The suspension was vortexed for 10 s, cooled on ice for 15 min, and centrifuged at 10,000 x g for 20 min. The nucleic acid was precipitated from the aqueous phase with an equal volume of isopropanol at -20°C for 1 h; this was followed by centrifugation at 10,000 x g for 20 min. The pellet was redissolved in 150 ,u of the chaotropic solution and was precipitated again in isopropanol at -20°C for 1 h. After centrifugation for 10 min, the RNA pellet was washed with 70% ethanol and was An additional primer (MV04) was designed in the antisense orientation to be used with the MV03/MV05 product as a nested primer to provide additional confirmation of the sequence of the amplified product (Table 1) .
Control amplifications for the extracted nucleic acid in the clinical samples were performed with oligonucleotide primers from the HLA-DQa gene (18) , yielding a 242-bp PCR product.
Clinical samples, IFA, and virus culture. Nasal aspirates in sterile PBS were collected from 38 children evaluated for MV and other respiratory virus infections as described previously (23) . The To further confirm the specificity of the PCR product, 1 ,ul of PCR product was reamplified (under the conditions described above) for nine cycles, with the MV04 hemi-nested primer used in conjunction with MV03, and the PCR product was analyzed by electrophoresis in a 4% gel (3% NuSieve agarose, 1% standard agarose).
Additional confirmation of the specificity of the PCR product was derived from restriction enzyme digestion of 10 ,ul of PCR product with 4 U ofAccI (GIBCO BRL) incubated overnight at 370C. Digestion of the amplified product was predicted to yield two fragments (191 and 224 bp), which were resolved by analysis on a 4% agarose gel.
RESULTS
Selection of primers. The structure of the MV genome and the location of the primer pairs are shown in Fig. 1 . We tested the sensitivity of the three primer pairs at different concentrations of template [peMV(-)] (Fig. 2) . The results indicated superior amplification with the MV03/MV05 primers. The remaining primer pairs were not examined further. We determined the optimal concentration of MgCl2 (2.5 mM) and the optimal annealing temperature (60°C) for this primer pair (data not shown). All (11, 16a) .
Sensitivity of PCR for the MV genome. The sensitivity of our PCR assay for detection of the MV genome is shown in Fig. 3 . As few as 3,000 virus equivalents as cDNA (50 fg of plasmid DNA) could be detected by direct examination of 50% of the PCR product from a 20-,u reaction resolved on a 2% agarose gel stained with ethidium bromide. Southern hybridization increased the sensitivity of detection down to 30 virus particle equivalents as cDNA (0.5 fg). Amplification of as little as 1 PFU of MV stock of known titer yielded a clear ethidium bromide-stained band of the predicted molecular mass (data not shown). Table 2 . A single PCR product of the predicted size (415 bp) was amplified from 300 ,ul of nasal aspirate from the 14 patients from whom MV was cultured. The derivation of the PCR product from the MV genome was confirmed byAccl digestion of the PCR product and hemi-nested amplification with the MV03/MV04 primer pairs, which yielded the anticipated fragments (191 and 224 bp for the AccI digestion and 251 bp for the hemi-nested PCR) when resolved on a 4% agarose gel (data not shown). Southern hybridization with an MV-specific oligonucleotide probe further confirmed the identity of the PCR product (Fig. 4 ).
For four patients (patients 19, 24, 31, and 13) for whom virus culture results were either lost (patient 13) or negative (three patients), the MV genome was detected by PCR analysis of their nasal secretions that were also positive by IFA. Three patients (patients 19, 24, and 31) had positive IgM serology for MV. No serology was available for patient 13 . All four patients had fever and Koplik spots and an exposure history consistent with MV infection.
Three patients (patients 25, 34, and 35) were positive for MV by IFA but were negative for MV by virus culture and PCR. No amplifiable nucleic acid could be detected in the nasal secretion of one of the patients (patient 25). The presence of an inhibitor to PCR DNA amplification was ruled out by spiking 0.6 ,ug of human genomic DNA into the reaction with the HLA-DQa primers, which yielded the anticipated 242-bp product. Repeat extraction of an aliquot of nasal secretion from this patient again failed to yield amplifiable nucleic acid. Serology was negative for IgM and positive for IgG on the second day of her illness, which suggests that the patient did not have acute MV infection.
For the two remaining IFA-positive, culture-negative patients, no MV genome was detected in their nasal secretions, even though HLA-DQa sequences were detected. In one patient with a negative culture (patient 35), there was a delay of 4 from seven of these patients (Table 2 ), but no cross-reactivity was noted by PCR with the MV-specific primers. Amplification with the HLA-DQot primers yielded the anticipated 242-bp product in 16 of 17 patients.
DISCUSSION
We reported here the sensitive and specific amplification of the MV genome from nasal aspirates from acutely ill pediatric patients. A PCR assay that permits the reverse transcription of extracted RNA and the amplification of the cDNA in a single tube was devised. The assay was sufficiently sensitive to permit direct visualization of the resolved PCR product on a 2% agarose gel without a need for nested amplification or Southern hybridization except to further confirm the identity of the amplified sequence.
The PCR assay compared favorably with culture and IFA. The rapid availability of a result (1 versus 10 to 23 days) and the enhanced sensitivity (samples from three patients were culture negative but PCR, IFA, and MV IgM positive) were distinct advantages of the PCR assay over culture for MV. The ease of interpretation of PCR results and the ability to perform the test on archival samples were additional advantages. The potential problems of false-positive IFA results are highlighted by the conflicting data for patients 25 and 34. In choosing the optimal assay for any given clinical setting, one must weigh the possible disadvantages of the PCR (potential for contamination resulting in false-positive results and the labor-intensive nature of the procedure) against the advantages (rapid availability of easily interpreted results).
The oligonucleotide primers and probe used in our study were specifically designed to amplify conserved regions of the genome shared by other members of the Morbillivirus genus. While clinical isolates of MV all share serologic cross-reactivities, genomic sequence variation has been documented in wild-type isolates (5, 16, 24) . Our primers would be expected to amplify the RNA of currently circulating MV isolates on the basis of analysis of matrix gene sequences from clinical isolates from the United States and the published sequences of four wild-type isolates from Great Britain (5, 22) . All four isolates shared 100% homology with the MV03 and MV05 primers and three of four isolates had a single-base-pair mismatch with the MV04 primer. The MV03/MV05 primer pair successfully amplified a sequence of the predicted length from canine distemper virus RNA, further confirming the broad range of this primer pair (data not shown).
The amplifications of HLA-DQao sequences used to verify the presence of amplifiable nucleic acid were negative from three patients. In one case (patient 28), the MV amplification was positive, which suggested the preferential stability of the encapsidated MV genome compared with that of cellular nucleic acid during storage and freeze-thaw cycles. Use of primers that hybridize to different exons of a host cell gene (e.g., ,B-actin primers from exons 4 and 5 [3] ) and that therefore yield PCR products of different lengths from RNA or DNA templates would be suitable controls for this RT PCR assay.
Other reports have described PCR assays for detection of the MV genome in specialized clinical settings. Godec et al. (8) and Schmid et al. (21) designed primers from different MV genes to amplify MV sequences from frozen and formalin-fixed brain tissues from patients with subacute sclerosing panencephalitis. Jackson et al. (9) used PCR primers from the nucleocapsid gene to amplify MV RNA from lung tissue from an immunocompromised patient who died of giant cell pneumonia. In none of those studies was an effort made to choose primers capable of hybridizing to a potentially wide range of different MV isolates. In a fourth study, degenerate primers were designed to amplify a conserved region in the nucleocapsid genes of MV, canine distemper virus, parainfluenza virus type 3, and Sendai virus (15) . These studies, in conjunction with the present one, document the wide range of primers available for detection of MV in different clinical and research applications.
In designing our assay, we made efforts to eliminate, where possible, opportunities for PCR contamination by both the exogenous template and the PCR product. The reverse transcription and gene amplification steps were carried out in a single reaction tube, with the RNA template protected by an overlay of mineral oil. Incorporation of dUTP into the reaction mixture would have permitted use of uracil-N-glycosidase, according to published protocols (12) , if contamination of reactions by previously synthesized product had occurred.
In summary, we reported the sensitive and specific detection of MV matrix gene sequences in nasal aspirates from infected patients. This assay should provide a useful addition to the currently available modalities for the detection of MV infection.
